Member Info for Bella6532

Avacta gave LG Chem an exclusive affimer licence deal for certain ones. Could they simply be trying to negotiate a sale with affimer licence deal hence the slightly longer time needed to get all the terms agreed.

Geez guys..you are invested in a UK based company and it's Starmers bunch of idiots who have taken a wrecking ball to the UK economy not Trump and now they're goung to try and put the blame for their almighty cxxx ups on Trump making things worse.

The US debt is equivalent to $100,000 per head of its population. So yes I agree with what he's doing. A short sharp shock to bring countries to the negotiating table. He also realises how fragile the global supply chains are and he want to try and on shore critical manufacturing...pharma being one (antibiotics for instance) etc etc...

Many on here won't agree with what he's doing but that's OK too.

At the end of the day we will see how it pans out...but no one should be surprised by what he's done he's been talking about the unfairness for many years and he ran for election saying it daily.

Oddmoney...I know but our American friends have asked why does the UK charge both? They feel it would be much fairer to charge one or the other.

If I've read it correctly their supplier is Starshine Chemical in China.

4.5m traded today...now that wasn't all bad was it?

Well it recovered quicker than even I thought and the overall markets will do the same too. PI's get spooked reading gheir news feeds and social media. The Reeves budget will do far more harm to the UK economy than US tariffs. Why should US tax payers foot the bloated UK welfare state and migrant hotels anyway through the 10-12% customs duty and VAT on shipping costs the UK has been charging on US imports??? If we are so hard done to now surely they were over the past few years...pot and kettle comes to mind.

Geez...real scardy cats today....it'll all bounce back in a couple of weeks...if not by the end of this week.

BV..I didn't say AVA3996 was Bortezomib and neither does Avacta which is who wrote the blurb I posted.

Avacta has lots of work going on in the background and all companies change direction due to new info/knowledge/findings and market sentiment etc.

It could have been shelved or withdrawn back into the lab for tweeking etc...who knows. Lab work on a product doesn't always lead to that product seeing the light of day but it can help backup work on other more relevant products.

OK so ghat was old info as AVA3996 is no longer in the current pipeline. Was it worked up to target Takeda as a possible partner. Has Takeda moved on to other treatments making AVA3996 a no goer....

'Pre-clinical data generated to date and presented at AACR show that:

The release of the active proteasome inhibitor (AVA2727D) from AVA3996 is specific to the enzyme FAP, which is upregulated in most solid tumours. This underpins the potential to target the proteasome inhibitor to tumour tissue.

In a head to head study, AVA2727D kills cancers cells (ex-vivo) as effectively as bortezomib (Takeda’s Velcade) which is one of the approved proteasome inhibitors on the market.

In three different in-vivo (mouse) cancer models (melanoma, sarcoma and colorectal cancer), AVA3996 was as effective as bortezomib in restricting tumour growth, and in the case of the melanoma model, as effective as trametinib, the standard of care for unresectable melanoma.

The significant toxicities associated with bortezomib observed in these in-vivo models were not observed in the case of AVA3996, suggesting that the systemic exposure to the drug had been reduced due to the tumour targeting of the pre|CISIONTM chemistry in AVA3996.'

Https://pubmed.ncbi.nlm.nih.gov/19410573/

Https://www.tempus.com/news/tempus-announces-expansion-of-collaboration-with-takeda-to-leverage-multimodal-real-world-datasets-and-biological-model-systems-in-oncology-research-and-development/?srsltid=AfmBOor2M1G6C4VHdjqSugf9pi6D3Zy_Sjh9hx7Z9aCgmi-qKthdTyrt

See any similarities with what Avacta might attempt to do next...

https://ir.glycomimetics.com/news-releases/news-release-details/glycomimetics-enters-acquisition-agreement-crescent-biopharma

From article dated 15 Feb 2025

'In other recent news, GlycoMimetics Inc. is experiencing significant changes in its executive leadership and is undergoing measures to regain Nasdaq compliance. Two key executives, CEO Harout Semerjian and CFO Brian Hahn, have announced their intention to leave the company by March 31, 2025. This development comes as GlycoMimetics is in the process of a proposed merger with Crescent Biopharma, Inc., with both executives set to provide consulting assistance during the transition.

In addition, GlycoMimetics has been granted an extension until June 16, 2025, to meet Nasdaq's minimum bid price requirement according to a recent SEC filing. The company's common stock has been transferred to the Nasdaq Capital Market as it works to elevate its closing bid price to at least $1.00 per share for a minimum of 10 consecutive business days.

These are the latest developments for GlycoMimetics, with the company actively monitoring its stock's bid price and considering options to address the deficiency. The company's future compliance with Nasdaq's requirements and the successful completion of the merger with Crescent Biopharma will be closely followed by investors and industry watchers.'

Https://www.fiercebiotech.com/biotech/crescent-inks-glycomimetics-merger-securing-nasdaq-listing-and-200m-hot-cancer-program

Https://ir.glycomimetics.com/news-releases/news-release-details/glycomimetics-enters-acquisition-agreement-crescent-biopharma

Don't recall this info being mentioned elsewhere by Avacta..why not?...it makes more sense as to why they inserted a 2W dosing trial.

And the Coris sale could be to the same company who bought Launch but just taking a little longer to complete due to Affimer IP.

Codejunkie...'Before they even think about NASDAQ, MCAP needs to be much bigger and the CLN needs to be gone.'...not so...they can do a RTO with a fundraise on the back of it...happens all the time.